If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
Agree Timster. Clearly there would be an incentive for BP to get a license deal done prior to public release of P1a data to avoid a competitive process with others. I am sure there will be some sort of VDR available under NDA which provides enough substance to at least start DD - all BP will likely be in this. BP could also provide an indicative offer subject to conditionality following cohort 7 data release.
Would Avacata want to agree a deal pre data-release to encourage competition? Depends on the offer and how good the data is looking I suppose.
Exciting times.
Janet Munro Head Program Innovation, Global Drug Development at Novartis:
"Interested to hear progress on the first therapeutic from Avacta’s platform, Sujood from LSE described as a treatment paradigm changer in oncology. Fingers crossed for THAT RNS!"
Terry panicking - love to see it.
It is so clear you are not an investor - you play this card to have ‘relevance’ on this board and to cover up the fact you are sad and short.
No way would an investor have such a negative perception on a holding and try to spread FUD.
If you had such concerns head to the AGM and ask the questions. You would be laughed out the door.